Display options
Cite
Wei CR, Liu J, Yu XJ. Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis. Int J Clin Exp Med. 2015;8(12):22139-48
Wei, C. R., Liu, J., & Yu, X. J. (2015). Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis. International journal of clinical and experimental medicine, 8(12), 22139-48.
Wei, Chang-Rong, et al. "Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis." International journal of clinical and experimental medicine vol. 8,12 (2015): 22139-48.
Wei CR, Liu J, Yu XJ. Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis. Int J Clin Exp Med. 2015 Dec 15;8(12):22139-48. eCollection 2015. PMID: 26885188; PMCID: PMC4729974.
Copy Download .nbib Format: NLM
Share it on

Int J Clin Exp Med. 2015 Dec 15;8(12):22139-48. eCollection 2015.

Targeting SLUG sensitizes leukemia cells to ADR-induced apoptosis.

International journal of clinical and experimental medicine

Chang-Rong Wei, Jun Liu, Xiao-Jun Yu

Affiliations

  1. Department of Haematology, People's Hospital of Linyi Linyi, Shandong, China.
  2. Department of Pharmacy, Chest Hospital of Linyi Linyi, Shandong, China.
  3. Department of Infection Emergency, People's Hospital of Linyi Linyi, Shandong, China.

PMID: 26885188 PMCID: PMC4729974

Abstract

BACKGROUND AND AIMS: Slug is an E-cadherin repressor and a suppressor of PUMA (p53 upregulated modulator of apoptosis) and it has recently been demonstrated that Slug plays an important role in controlling apoptosis. In this study, we examined whether Slug's ability to silence expression suppresses the growth of leukemia HL-60 cells and/or sensitizes leukemia HL-60 cells to adriamycin (ADR) through induction of apoptosis.

METHODS: SLUG siRNA was transfected into the HL-60 and HL-60(ADR) cell lines (an adriamycin resistant cell line). The stably SLUG siRNA transfected HL-60 and HL-60(ADR) cells was transiently transfected with PUMA siRNA. The mRNA and protein expression of SLUG and PUMA were determined by Quantitative real-time RT-PCR and Western blot assay. The effects of SLUG siRNA alone or combined with ADR or PUMA siRNA on growth and apoptosis in HL-60 and HL-60(ADR) cells was detected by MTT, ELISA and terminal deoxynucleotidyl transferase-mediated nick end labeling (TUNEL) assay.

RESULTS: The results showed that SLUG was less expressed in the HL-60 cells, and high expressed in the HL-60(ADR) cells. Obvious down-regulation of SLUG mRNA and protein levels and up-regulation of PUMA mRNA and protein levels after SLUG siRNA transfection was showed in the HL-60(ADR) cells. Treatment with ADR induced SLUG mRNA and protein in the HL-60 cells. Significant positive correlation was observed between basal SLUG mRNA and protein and ADR sensitivity. SLUG gene silencing by SLUG siRNA transfection inhibited growth and induced apoptosis, and increased ADR killing of the HL-60 and HL-60(ADR) cell lines. After the SLUG siRNA transfected HL-60 and HL-60(ADR) cells was transiently transfected with PUMA siRNA, did not increase ADR killing of the HL-60 and HL-60(ADR) cell lines.

CONCLUSION: SLUG level positively correlated with sensitivity to ADR. SLUG siRNA could effectively reduce SLUG expression and induce PUMA expression and restore the drug sensitivity of resistant leukemic cells to conventional chemotherapeutic agents.

Keywords: Myeloid leukemia; PUMA; SLUG; cytarabine

References

  1. Curr Cancer Drug Targets. 2012 Jun;12(5):571-96 - PubMed
  2. J Clin Oncol. 2009 Dec 10;27(35):6041-51 - PubMed
  3. Mol Cell. 2001 Mar;7(3):683-94 - PubMed
  4. Med Oncol. 2011 Dec;28 Suppl 1:S301-9 - PubMed
  5. Mol Cell. 2001 Mar;7(3):673-82 - PubMed
  6. Clin Cancer Res. 2005 Feb 1;11(3):1174-80 - PubMed
  7. Br J Haematol. 2004 Nov;127(3):264-79 - PubMed
  8. Mol Pharmacol. 2010 Mar;77(3):483-94 - PubMed
  9. Int J Cancer. 2009 May 1;124(9):2186-99 - PubMed
  10. Cancer Cell. 2003 Oct;4(4):248-9 - PubMed
  11. J Pathol. 2007 Apr;211(5):507-15 - PubMed
  12. Cancer Res. 2014 Jul 15;74(14 ):3695-706 - PubMed
  13. Oncogene. 2005 Apr 28;24(19):3073-82 - PubMed
  14. Cancer Res. 2002 Dec 15;62(24):7316-27 - PubMed
  15. Dev Dyn. 1998 Oct;213(2):182-7 - PubMed
  16. Oncologist. 2007 Mar;12(3):341-55 - PubMed
  17. Cell. 2005 Nov 18;123(4):641-53 - PubMed
  18. Mol Cell. 1999 Sep;4(3):343-52 - PubMed
  19. Haematologica. 2007 Nov;92(11):1519-32 - PubMed
  20. Mol Cell Biol. 2000 Jul;20(14 ):5087-95 - PubMed
  21. Expert Opin Investig Drugs. 2012 Feb;21(2):179-89 - PubMed
  22. Oncogene. 2007 Jun 21;26(29):4189-98 - PubMed
  23. Br J Cancer. 1989 Aug;60(2):206-10 - PubMed
  24. Exp Mol Med. 2010 Jun 30;42(6):428-36 - PubMed
  25. Cell Death Differ. 2009 Sep;16(9):1192-202 - PubMed
  26. Science. 1994 May 6;264(5160):835-9 - PubMed
  27. Clin Cancer Res. 2009 Feb 15;15(4):1126-32 - PubMed
  28. Am J Hematol. 2013 Apr;88(4):318-27 - PubMed
  29. Cell Signal. 2010 Aug;22(8):1247-53 - PubMed

Publication Types